Anteris Technologies Global Corp.

Anteris is a structural heart company focused on cardiac care through advancements to restore heart valve patients to healthy function. Its lead product is the DurAVR® THV System, designed to treat aortic stenosis, a condition caused by a narrowing of the aortic valve. The balloon-expandable DurAVR® THV is a biomimetic valve, shaped to mimic a healthy human aortic valve and replicate normal aortic blood flow. The DurAVR® THV System includes a single-piece, biomimetic valve made with the proprietary ADAPT® tissue-enhancing technology and deployed with the balloon expandable ComASUR® Delivery System. ADAPT® is an anti-calcification tissue shaping technology that reengineers xenograft tissue into a pure, single-piece collagen bioscaffold. Patented ADAPT® tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure, according to "Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes" by William Neethling et. al., and has been distributed for use in over 55,000 patients globally in other indications. The ComASUR® Delivery System is designed to provide precise alignment with the heart's native commissures for accurate placement of the DurAVR® THV. As of December 2025, more than 130 patients worldwide have been implanted with the DurAVR® THV. Aortic stenosis is a common and serious valvular heart disease, fatal in approximately 50% of patients if untreated after two years, with no available pharmacotherapy.